Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gMSC1
- Development stage
- Unknown
- Lead developer
- Two Cells
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
gMSC1 is an investigational allogeneic cell therapy developed by TWOCELLS Co., Ltd. for the treatment of focal knee cartilage defects, including those associated with traumatic injury, osteochondritis dissecans, or focal osteoarthritis. The product consists of donor-derived synovial mesenchymal stem cells (MSCs) that are mass-produced using proprietary serum-free culture technology (STK1 and STK2 media). These cells are formulated into a scaffold-free, three-dimensional artificial tissue known as a Tissue-Engineered Construct (TEC). When surgically implanted into a knee cartilage defect, gMSC1 is intended to promote the regeneration of functional hyaline-like cartilage. The development of gMSC1 has been supported by various Japanese government agencies and is being conducted in partnership with Kaken Pharmaceutical, which holds joint development and exclusive marketing rights in Japan.
- Brand names
- gMSC 1gMSC1gMSC-1
- Other names
- TECTissue-Engineered Constructallogeneic synovial mesenchymal stem cells
Beyond the preview
Go deeper on gMSC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gMSC1.